Amphotropic but not atherotropic: another caveat for adenoviral gene therapy.

The Journal of clinical investigation ·Vol. 95 ·No. 6 ·1995-06-00 ·Pages 2425-6

Casscells W, Willerson JT

Abstract

暂无摘要

MeSH Terms

Adenoviruses, Human/genetics Animals Genetic Therapy/methods Genetic Vectors Muscle, Smooth, Vascular Rabbits Transduction, Genetic

Authors & Affiliations

2 authors, click to expand affiliations / ORCID

Casscells W

Willerson J T

References (19)

19 references, click to expand

A novel gene delivery system using EGF receptor-mediated endocytosis.
FEBS Lett. 1994 Jan 31;338(2):167-9 PMID: 8307175
Smooth muscle cell expression of extracellular matrix genes after arterial injury.
Am J Pathol. 1994 Jun;144(6):1348-56 PMID: 8203472
Local drug delivery for the prevention of restenosis. Fact, fancy, and future.
Circulation. 1994 Oct;90(4):2070-84 PMID: 7923695
The advent of adenovirus. Gene therapy for cardiovascular disease.
Circulation. 1993 Oct;88(4 Pt 1):1937-42 PMID: 8403339
Amphotropic but not atherotropic: another caveat for adenoviral gene therapy.
J Clin Invest. 1995 Jun;95(6):2425-6 PMID: 7769084
Localization of basic fibroblast growth factor in bovine endothelial cells: immunohistochemical and biochemical studies.
Exp Cell Res. 1993 Feb;204(2):247-59 PMID: 8440322
Na(+)-H+ exchange inhibitors decrease neointimal formation after rat carotid injury. Effects on smooth muscle cell migration and proliferation.
Circ Res. 1993 Aug;73(2):269-75 PMID: 8392448
Expression and subcellular distribution of basic fibroblast growth factor are regulated during migration of endothelial cells.
Circ Res. 1994 Mar;74(3):485-94 PMID: 8118957
Making clinical grade gene therapy vectors.
Hum Gene Ther. 1994 Aug;5(8):925-6 PMID: 7948141
Gene therapy inhibiting neointimal vascular lesion: in vivo transfer of endothelial cell nitric oxide synthase gene.
Proc Natl Acad Sci U S A. 1995 Feb 14;92(4):1137-41 PMID: 7532305
Anatomic barriers influence the distribution of in vivo gene transfer into the arterial wall. Modeling with microscopic tracer particles and verification with a recombinant adenoviral vector.
Arterioscler Thromb. 1994 Jan;14(1):148-61 PMID: 8274471
Defective parvoviruses may be good for your health!
Prog Med Virol. 1993;40:193-205 PMID: 8438076
Elimination of smooth muscle cells in experimental restenosis: targeting of fibroblast growth factor receptors.
Proc Natl Acad Sci U S A. 1992 Aug 1;89(15):7159-63 PMID: 1323129
Low level in vivo gene transfer into the arterial wall through a perforated balloon catheter.
Circulation. 1992 Mar;85(3):1110-7 PMID: 1537109
Targeted vectors for gene therapy.
FASEB J. 1995 Feb;9(2):190-9 PMID: 7781922
Inactivation of E2a in recombinant adenoviruses improves the prospect for gene therapy in cystic fibrosis.
Nat Genet. 1994 Jul;7(3):362-9 PMID: 7522742
Gene therapy for vascular diseases.
Tex Heart Inst J. 1994;21(1):98-103 PMID: 8180517
The pathogenesis of atherosclerosis: a perspective for the 1990s.
Nature. 1993 Apr 29;362(6423):801-9 PMID: 8479518
Targeted integration of transfected and infected adeno-associated virus vectors containing the neomycin resistance gene.
Gene Ther. 1994 May;1(3):165-9 PMID: 7584077

Article Info

Journal

The Journal of clinical investigation

Abbr.

J Clin Invest

ISSN

0021-9738

DOI

10.1172/JCI117938

Published

1995-06-00

Pages

2425-6

Language

English

Region

United States

NLM ID

7802877

PMCID

PMC295908

Subset

Corrections

CommentOn

PMID: 7769106

External Links

PubMed source DOI: 10.1172/JCI117938 PMC Full Text View journal details

Analysis Services

Amphotropic but not atherotropic: another caveat for adenoviral gene therapy.

Contact

WeChat Official Account